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Objectives: Complications in instrumental spinal surgeries (ISS) pose a consider-
able burden on patients. Necessary reoperations are associated with significant 
resource utilization and cost and from the perspective of the German Statutory 
Health Insurance (SHI). Dependable data on the frequency of reoperations and 
associated costs are lacking for Germany. The aim of this study was to estimate 
the incidence of ISS and consecutive reoperations, and to calculate the related 
costs. MethOds: We conducted a retrospective claims data analysis using the 
Health Risk Institute research database, which contains anonymized claims data 
and covers approximately 5.42% of the German population. The study period 
comprised 01 January 2009 to 31 December 2011. An algorithm of operation and pro-
cedure codes (OPS) identified primary ISS and following reoperations. Reoperation 
rates were calculated for an individual period of 12 months after the primary ISS in 
2010. Annual costs for reoperations were calculated based on group comparison of 
patients with reoperation and those without reoperation (control group). Existing 
differences in cost levels in the year before the primary ISS were adjusted by the 
difference in differences approach. Results: A total of 3,316 individuals had a 
primary ISS in 2010. The reoperation rate was 9.98% (95% CI = 8.98% to 11.02%). 
Mean cost per ISS was € 11,331 for all patients (€ 13,358 reoperation group, € 11,106 
control group). The mean adjusted annual cost for a reoperation was € 11,370, with 
€ 8,432 directly attributed to the reoperation procedure and € 2,938 to excess costs 
in the first year after the primary ISS. cOnclusiOns: The direct cost of ISS has a 
significant impact on health insurance budgets. With 10% of primary ISS patients 
requiring a reoperation in Germany, their associated annual costs are relevant from 
the SHI perspective. As demonstrated elsewhere, these cost might be partly avoid-
able by using intra-operative 3-D imaging with navigation.
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Objectives: This study aims to estimate the incidence and costs of osteoporotic 
fractures in The Netherlands in 2010 and project them to 2030. MethOds: The 
incidence and health care costs of fractures were derived from claims data of 
all health care insurers in The Netherlands. We obtained 5-year age- and gen-
der-specific costs of patients with and without fractures. Cost included hospi-
tal admission, physical therapy, occupational therapy, general practitioner and 
medication. In order to attribute fractures to osteoporosis we used a large dataset 
from a general hospital that included patients with a fracture screened with Dexa 
scan. Future projections were based on four different scenarios: 1. demographic 
scenario, 2. demographic+trend in incidence scenario, 3. demographic+trend in 
incidence+trend in cost scenario, and 4. increased treatment scenario. Results: 
Of all registered fractures 32% could be attributed to osteoporosis. In women this 
percentage was larger than in men (36 versus 21 %). This resulted in an incidence 
for all osteoporotic fractures of 964 per 100.000 in women and 245 per 100.000 in 
men for 2010. Over time (2010-2030) the overall increase in incidence of osteo-
porotic fractures was 40% (scenario 1). The increase in hip fractures ranged from 
60% (scenario 1) to 79% (scenario2). In 2010 approximately 200 million Euros was 
spend on treatment of osteoporotic fractures. The costs for osteoporotic fractures 
increased with 50% from 2010 till 2030 (scenario 1). The increase in costs for hip 
fractures was highest, ranging from 60% (scenario1) to 148% (scenario 3&4 com-
bined), resulting in cost estimates in 2030 of 161 and 249 million, respectively. 
Prevention of osteoporotic fractures in general can lead to cost-savings of 92 mil-
lion in 2030 (scenario 4 & 1 combined). cOnclusiOns: The expected high increase 
in incidence and costs of osteoporotic fractures calls for a wider use of prevention 
and treatment options.
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Objectives: Ankylosing spondylitis (AS) entails an individual burden to patients 
and ties up resources. This study aimed to assess the total costs of AS, includ-
ing the indirect burden of AS patients in Hungary and to obtain an overview of 
patients’ status, demographics, morbidity, working capacity and other charac-
teristics. MethOds: Between January–March 2014, a questionnaire survey was 
conducted among AS patients, which was filled out voluntarily and anonymously. 
Missing data was not imputed in the analysis; considered patient number is pre-
sented next to results if lower than total patient number. Results: 152 patients 
completed the questionnaire, of which 37% were women. Mean age was 51 years 
(Standard Deviation [SD]: 13 years) and average disease duration was 17 years 
(SD: 12 years). At primary diagnosis of AS, 80% of patients had a full-time job, 2% 
a part-time job, and only 8% received disability pension. At time of survey, only 
36% of patients worked full-time, 1% part-time, and the proportion of disability 
pensioners increased to 42%. Cost calculation results* showed that the average 
annual total cost per AS patient was 5,155€ . Within this, average annual direct non-
medical cost was over 1,976€ and average annual indirect cost per patient was 
approximately 3,129€ (145 patients). Wage loss due to disability pension generated 
the highest average annual indirect cost per patient (3,290€ – 124 patients). In the 
working-age population (118 patients, 31–62 years), total average cost per patient 
was 5,996€ . cOnclusiOns: Due to their disease, AS patients can become par-
tially or completely disabled, which imposes a significant burden directly on their 
environment and indirectly to society. Average costs were associated with disease 
duration. Patients may already be driven out from the labour market in their active 
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Objectives: Lumbar spinal stenosis (LSS) occurs as a degeneration of the spine 
in aging populations. Treatment options comprise surgical and non-surgical 
intervention. The aim of this study was to compare annual costs between LSS 
patients treated with instrumental spinal surgery (ISS) and those non-surgically 
treated. MethOds: A retrospective claims data analysis was conducted using 
anonymized claims data from the Health Risk Institute research database. The study 
period comprised 01 January 2009 to 31 December 2011. LSS patients receiving an 
ISS were compared to an age and gender matched non-operated control group with 
comparable disease state. Patients were identified by ICD-10-GM code M48.0* in the 
inpatient setting. Operation and procedure codes (OPS) were used to identify ISS. 
Comparable disease state was achieved by matching total costs in an individual 
period of 12 months before the first LSS caused hospitalization. Annual costs after 
surgical treatment were compared for LSS patients receiving ISS and those with no 
surgical treatment. Results: A total of 2,027 patients with LSS were identified in 
2010 records. Surgical treatment with ISS was applied in 542 cases whereas 1,485 
individuals received non-surgical treatment. After matching both groups for age, 
gender, and comparable disease state, 393 patients in each group were available for 
the cost comparison. Mean annual costs were € 8,458 higher in the ISS-treated group; 
clearly due to average ISS-cost of € 9,644. In contrast, costs for outpatient care and 
pharmaceuticals decrease after the surgery. cOnclusiOns: Surgical treatment for 
LSS patients exceeds the cost of non-surgical treatment in the first year after sur-
gery. A cost offset is not achievable in this period due to the high cost of the surgical 
intervention. Nevertheless, cost savings were already observed in pharmaceutical 
therapy and outpatient care. Further research is needed to determine if overall cost 
savings could be achieved in an extended timeframe.
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Objectives: The purpose of this study was to estimate the annual costs and the 
cost per responder for psoriatic arthritis (PsA) patients treated with apremilast, 
etanercept, and adalimumab in adults with PsA in the United States. MethOds: 
Comparative efficacy data were obtained from a Bayesian network meta-analysis 
of biologic and non-biologic disease-modifying antirheumatic drugs as of October 
2013. The primary outcome was ACR20 response at Week 24. Response rate dif-
ferences from the clinical trials were assumed to be maintained for 52 weeks. US 
wholesale acquisition cost as of June 2014 and approved labeled dosing were used 
to derive drug treatment costs. Results: At Week 24, the adjusted ACR20 response 
rate was 40.3% for apremilast, 53.4% for etanercept, and 57.8% for adalimumab. 
The cost per ACR20 responder at Week 24 was $23,562 for apremilast, $30,346 for 
etanercept, and $25,978 for adalimumab. By Week 52, the cost per ACR20 responder 
was $53,704 for apremilast, $65,750 for etanercept, and $56,273 for adalimumab. The 
annual cost to achieve 100 responders was $5,370,387 for apremilast, $6,574,981 for 
etanercept, and $5,627,336 for adalimumab. cOnclusiOns: Apremilast had the 
lowest wholesale acquisition costs per ACR20 responder and the lowest annual cost 
to achieve 100 ACR20 responders, as compared with etanercept and adalimumab 
through 52 weeks in PsA patients.
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Objectives: Direct non-medical costs may be difficult to assess, so these are often 
disregarded in cost-of-illness studies. This analysis aims to estimate the annual 
direct non-medical costs of treating a patient with Rheumatoid Arthritis (AR) in 
Portugal, per level of disease activity. MethOds: Patients with RA followed by 5 
different rheumatologists across the country, were asked to participate in a survey, 
and informed consent was given by all patients. Besides socio-economic data, the 
survey included questions regarding the following cost components: number of 
medical appointments and treatments attended by the patient and its associated 
travel expenses; expenditures related to adaptations made to their homes and the 
purchase of medical devices; amount of domiciliary support received, both paid 
and unpaid. In case of paid domiciliary support patients were also asked about the 
associated amount. That figure was then used in order to assess the value of unpaid 
domiciliary support. Disease activity was measured by the DAS28 score. Results: 
Our final sample consists of 90 patients and descriptive statistics are in line with 
RA epidemiology (73 women, mean age 56.9). The percentage of patients with low 
disease activity was 27.7%, whereas, of 43.3% and 28.8% for those with moderate 
and high disease activity, respectively. Estimated direct non-medical costs ranged 
from € 1,339 to € 5,475 per year, for patients with low and high disease activity, respec-
tively. More than 70% of these costs were related to paid and unpaid domiciliary 
support. cOnclusiOns: Direct non-medical costs are positively associated with 
disease activity. Estimated costs have a non-negligible magnitude and are entirely 
borne by patients. Our results confirm the heavy economic burden that RA places 
on patients and their families.
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235 U (108)/200 U (100-440) was injected. Based on a BoNT-A injection interval of 12 
weeks, the annual cost per patient in the UK would be 1,068 GBP for abobotulinum-
toxinA, 1,198 GBP for onabotulinumtoxinA and 1,399 GBP for incobotulinumtox-
inA. cOnclusiOns: Considering the real life practice of BoNT-A injections and the 
comparison of treatment groups treated for the same limb segment, this analysis 
suggests that the use of abobotulinumtoxinA would result potentially in a reduction 
in the health care cost for the treatment of spasticity and that more patients could 
be treated with abobotulinumtoxinA with a given budget.
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Objectives: The objective is to compare the hospitalization length of stay and 
costs associated with comorbidities between dialysis patients and non-dialysis 
patients. MethOds: This was a cross-sectional observational study (from January 
to December 2010) of a national hospitalization database from the Brazilian Unified 
Public Healthcare System (Sistema Único de Saúde – SUS). Patients included in 
the study were hospitalized due to 3 predefined comorbidities categories: heart 
disease, vascular disease, and osteometabolic diseases, identified using ICD-10 
codes. Results: A total of 491,644 admissions were observed in patients not on 
dialysis (control group), while 2,627 admissions were identified in dialysis patients. 
The comparative analysis of causes of hospitalization showed that a larger propor-
tion of admissions due to heart disease was observed in patients on dialysis (61%) 
compared to the control group (47.9%), the opposite was observed for vascular and 
osteometabolic hospitalizations. For all 3 categories, cost of hospitalization for dialysis 
patients is at least two-fold higher and the length of stay almost 3 times longer (21 
days for dialysis patients versus 8 days for non-dialysis) than non-dialysis patients. 
The greatest differences between these two patient populations are in average costs 
among dialysis patients hospitalized for osteometabolic disorders versus control 
group and the highest burden regarding length of hospital stay, due to heart dis-
ease. cOnclusiOns: There is a high hospitalization burden among CKD-5D patients 
in the Brazil health care system. Since inpatient costs were the key cost drivers for 
CKD, strategies that reduce the risk of hospitalization and increase prevention of 
comorbidities may substantially decrease the overall health care economic burden.
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Objectives: Ankle sprains and fractures are common injuries affecting many 
individuals, often requiring substantial and costly medical interventions. Ankle 
injuries can have significant physical and economic consequences. Therefore, the 
objectives of this study were to systematically review and describe the literature 
on the direct and indirect costs related to the diagnosis and treatment of ankle 
sprains and fractures. MethOds: A systematic literature review of Ovid MEDLINE, 
EMBASE, Cochrane DSR, ACP Journal Club, AMED, Ovid Healthstar, and CINAHL was 
conducted for English-language studies on ankle sprains and fractures published 
from January 1980 to December 2013. Two reviewers assessed the articles for study 
quality using available giudelines and abstracted the data. Results: Overall, 1,415 
studies were identified of which 16 were selected for analysis. A majority of the 
studies were published in the last decade. The costs of ankle sprain diagnosis and 
management ranged from $495 to $4,667 per patient (2014 USD). The costs of stable 
ankle fracture diagnosis and management ranged from $89 to $602 per patient. 
However, the management costs were higher for unstable ankle fractures ($2,680 
to $15,095) and open fractures and varied depending on the severity of injury. The 
economic evaluations were conducted from the societal or health care system per-
spective. cOnclusiOns: The costs of diagnosing and treating ankle sprains and 
fractures varied among the studies mostly due to differences in injury severity 
and the study characteristics. Future studies undertaking economic evaluations 
should follow the available guidelines and ensure that their methods are transpar-
ent and understandable especially the study perspective and the valuation of the 
costs and outcomes.
PMS29
the PenSion CoStS oF MuSCuloSkeletal diSeaSeS. eStiMation oF the 
eConoMiC Burden Borne By the italian SoCial SeCurity SySteM
Russo S.1, Mariani T.T.2, Migliorini R.2, Marcellusi A.1, Mennini F.S.3
1University of Rome “Tor Vergata”, Rome, Italy, 2Istituto Nazionale della Previdenza Sociale, Rome, 
Italy, 3University of Rome “Tor Vergata”, Italy, Rome, Italy
Objectives: The aim of the study is to estimate the pension costs (social secu-
rity system in Italy is financed by public expenditure) induced by patients with 
musculoskeletal disorders (MD) and specifically for rheumatoid arthritis (RA), 
ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in Italy, between 2009 and 
2012. MethOds: We analysed the database of National Institute of Social Security 
(INPS) to estimate for MD, RA, AS and PsA, the total costs of for three types of 
social security benefits: disability benefits (for people with reduced work ability), 
disability pensions (for people who are not eligible to be considered as workers) 
and incapacity pensions (for people without work ability). Also was estimated the 
productivity loss for RA in the 2013 with data from the National Institute of Statistics 
and from national literature review. Results: From 2009 to 2012 were paid about 
320 thousand benefits at a cost of approximately € 1.7 billion, for an average of just 
over 80,000 performances a year with a cost of € 432 million per year. Specifically 
the total pension burden for RA was about € 99 million, for AS was € 26 million and 
for PsA was € 12 million. The loss of productivity for AR in 2013 amounted to € 
707,425,191 due to 162,360 workers with RA that determine 9,174,221 working days 
ages because of the disease’s symptoms and variability, leading to reduced social 
engagement. *exchange rate: 303,59HUF/EUR
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Objectives: Rheumatic diseases (RD) cause physical disability that may lead to 
early retirement, generating high indirect costs to society. We estimate these costs 
in the Portuguese population approaching the statutory retirement age. MethOds: 
Health, sociodemographic and occupational data was retrieved from the 4th 
National Health Survey (2005/2006), for all people between 50 and 64 years of age 
(3,762 men and 4,241 women), whilst an official wage national database was used 
to estimate productivity values by gender, age-group and region, using the human 
capital approach. The effects of RD on the likelihood of early retirement and the 
attributable fractions estimates were obtained at the individual level by logistic 
regression. Results: At the time of the survey, 37.2% of the population with ages 
50-64 years old self-reported at least one RD and among these 22.7% were officially 
retired, compared with 17.6% of those without RD (p< 0.001). Females had higher 
prevalence of RD (49.8% vs. 23.4% for males; p< 0.001). Presence of RD was associated 
with early retirement regardless of age, gender and region (OR= 1.3; CI 95%: 1.0 - 1.6). 
The estimated annual indirect costs following premature retirement attributable 
to RD were € 367 million (€ 504 per RD patient). Age-groups closer to the statutory 
retirement age contribute more to the overall indirect costs and also have higher 
individual productivity values. For instance, 60-64 years old age-group contribute 
with 52% of overall costs and had an average indirect cost of 699€ per RD patient. 
Females were responsible for about 55% of these costs, however males contrib-
ute with higher individual productivity losses (cost per patient: 788€ vs. 390€ , for 
males and females respectively). cOnclusiOns: Annual early retirement indirect 
costs attributable to RD are considerable. These results highlight the need to target 
patients with rheumatic conditions in order to obtain health and productivity gains 
and reduce early retirement in society.
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Objectives: Psoriatic arthritis (PsA) entails an individual burden to patients and 
ties up resources. This study aimed to assess the total costs of PsA, including the 
indirect burden of PsA patients in Hungary and to obtain an overview of patients’ 
status, demographics, morbidity, and working capacity. MethOds: Between 
January–March 2014, a questionnaire survey was conducted among PsA patients 
and filled out voluntarily and anonymously. Missing data was not imputed in the 
analysis; considered patient number is presented next to results if lower than total 
patient number. Results: 145 patients completed the questionnaire, of which 57% 
were women. Mean age was 54 years (Standard Deviation [SD]: 14 years) and aver-
age disease duration was 17 years (SD: 11 years). At primary diagnosis of PsA, 79% 
of patients had a full-time job, 4% a part-time job and only 3% received disability 
pension. At time of survey, only 32% of patients worked full-time, 4% part-time, and 
the proportion of disability pensioners increased to 28%. Cost calculation results* 
showed that the average annual total cost per PsA patient was 3,842€ . Within this, 
average annual direct non-medical cost was approximately 1,318€ (141 patients) and 
average annual indirect cost per patient was approximately 2,635€ (142 patients). 
Wage loss due to disability pension generated the highest average annual indirect 
cost per patient (2,734€ – 119 patients). In the working-age population (95 patients, 
31–62 years) total average cost per patient was 5,334€ . cOnclusiOns: PsA can 
cause patients to become partially or completely disabled, which imposes a signifi-
cant burden directly on their environment and indirectly to society. Average direct/
indirect costs are higher with longer disease duration and greater skin manifesta-
tions. Patients may already be driven out from the labour market in their active 
ages because of the disease’s symptoms and variability, leading to reduced social 
engagement. *exchange rate: 303,59HUF/EUR
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Objectives: To evaluate the real life practice of the use of botulinum toxin A 
(BoNT-A) in post-stroke upper limb spasticity and the economic consequences of 
fair comparisons of the dosing between either abobotulinumtoxinA (Dysport®) or 
onabotulinumtoxinA (Botox®) or incobotulinumtoxinA (Xeomin®). MethOds: 
ULIS-II is an observational, prospective study, conducted in 84 centers in 22 coun-
tries. Of 456 adults with post-stroke upper limb spasticity presenting for treatment 
with BoNT-A, 193 patients with the same injected limb segments “upper arm and 
lower arm” were analyzed for the dose injected for one cycle of BoNT-A. Treatment 
and concomitant interventions were in accordance with routine local clinical prac-
tice. Sample size, mean (SD)/median dose (min-max) in Unit for each BoNT-A and 
annual cost per patient were calculated using the mean dose administered and 
considering no vial sharing. An injection interval of 12 weeks was simulated for 
all BoNT-A treatments and the UK listed public price was used to ascertain annual 
cost. Results: For the abobotulinumtoxinA group (N= 141) a mean (SD)/median 
(min-max) dose of 665 U (280)/500 U (150-1500) was injected, for the onabotuli-
numtoxinA group (N= 37) a mean (SD)/median dose of 183 U (99)/200 U (50-500) 
was injected and for incobotulinumtoxinA (N= 15), a mean (SD)/median dose of 
